Tracleer® · Cardiovascular Tracleer blocks endothelin-1 receptors on vascular smooth muscle cells, preventing vasoconstriction and reducing pulmonary vascular resistance.
Phase 3 pipeline
ACT-293987 · Pulmonary Hypertension / Fibrosis ACT-293987 is a selective soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis.
EFI/ACT-385781A · Cardiovascular EFI/ACT-385781A is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics.
FDC macitentan/tadalafil · Cardiovascular This fixed-dose combination blocks endothelin-1 receptors (via macitentan) and phosphodiesterase-5 (via tadalafil) to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.
i.v. selexipag · Cardiovascular Selexipag is a prostacyclin receptor agonist that acts as a potent vasodilator.
iloprost (5 µg) · Cardiovascular Iloprost is a prostacyclin analogue that acts as a vasodilator and inhibits platelet aggregation.
macitentan (ACT-064992) · Cardiovascular Macitentan is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.
Macitentan/Tadalafil FDC · Cardiovascular This fixed-dose combination blocks endothelin-1 receptors (via macitentan) to reduce pulmonary vascular resistance while simultaneously inhibiting phosphodiesterase-5 (via tadalafil) to promote vasodilation in the pulmonary circulation.
selexipag (Uptravi) · Cardiovascular Selexipag is a prostacyclin receptor agonist that acts as a selective IP receptor agonist.